Brooklyn ImmunoTherapeutics, Inc.
(NYSE Amex Equities : BTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 1.10%162.160.7%$1254.93m
PFEPfizer Inc. 2.47%38.530.9%$1060.23m
MRKMerck & Co., Inc. 1.03%77.450.7%$958.24m
ABBVAbbVie, Inc. 1.02%107.981.9%$778.70m
BMYBristol-Myers Squibb Co. 1.54%65.431.0%$758.06m
LLYEli Lilly & Co. 1.76%189.201.1%$575.67m
AZNAstraZeneca Plc -0.18%50.741.2%$463.76m
GSKGlaxoSmithKline Plc 0.21%37.770.2%$217.86m
NVSNovartis AG 0.95%88.030.2%$157.01m
RPRXRoyalty Pharma Plc 0.53%41.870.2%$143.72m
VTRSViatris, Inc. 0.90%13.400.0%$127.48m
CVACCureVac NV 5.04%109.290.0%$96.11m
RGENRepligen Corp. -0.13%213.306.8%$86.07m
NVONovo Nordisk A/S 0.95%72.190.1%$62.10m
SNYSanofi 1.20%51.300.2%$61.19m

Company Profile

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.